Levotac-Max Tablet SR is a combination pharmaceutical formulation containing Ambroxol 75 mg, Levocetirizine 5 mg, and Montelukast 10 mg, designed for the effective management of respiratory conditions characterized by allergic and inflammatory components. Ambroxol, a mucolytic agent, facilitates the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a selective second-generation antihistamine, provides symptomatic relief from allergic manifestations such as rhinorrhea, sneezing, and nasal congestion by inhibiting peripheral H1 histamine receptors without causing significant sedation. Montelukast, a leukotriene receptor antagonist, mitigates bronchoconstriction, inflammation, and edema by blocking leukotriene D4 receptors in the airways, making it beneficial in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The sustained-release formulation ensures a prolonged therapeutic effect, enhancing patient compliance through once-daily dosing. Levotac-Max Tablet SR is indicated for the treatment of chronic bronchitis, asthma, allergic rhinitis, and other respiratory disorders where mucus hypersecretion, allergic inflammation, and bronchoconstriction coexist. It should be used under medical supervision, considering contraindications such as hypersensitivity to any component and caution in patients with hepatic or renal impairment.